(Total Views: 69)
Posted On: 07/03/2017 7:58:12 AM
Post# of 22811
$AVEO,,,Additional Info.:
AVEO Pharmaceuticals
AVEO managed to stay near the top of the list for a second week in a row, this pharmaceutical is working on cancer candidate treatments. Last week the company announced it had secured a $14 million in aggregate gross proceeds from its credit facility.
“AVEO now has resources that we expect will take us well past the anticipated first quarter 2018 readout of the TIVO-3 trial, our U.S. pivotal trial in third-line RCC,” Michael Bailey, president and CEO of AVEO said in a statement.
AVEO Pharmaceuticals gained 74.4 percent last week and traded at $2.17 per share.
AVEO Pharmaceuticals
AVEO managed to stay near the top of the list for a second week in a row, this pharmaceutical is working on cancer candidate treatments. Last week the company announced it had secured a $14 million in aggregate gross proceeds from its credit facility.
“AVEO now has resources that we expect will take us well past the anticipated first quarter 2018 readout of the TIVO-3 trial, our U.S. pivotal trial in third-line RCC,” Michael Bailey, president and CEO of AVEO said in a statement.
AVEO Pharmaceuticals gained 74.4 percent last week and traded at $2.17 per share.
(0)
(0)
'Everything works out in the end,,,If it hasn't worked out,,it's not the end'
https://twitter.com/twitter/statuses/957208055766241280
https://twitter.com/twitter/statuses/957208055766241280
Scroll down for more posts ▼
